SK bioscience appoints new executives
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
Subscribe To Our Newsletter & Stay Updated